No abstract available.
Hepatitis B* ; Hepatitis* ; Vaccination*

The study was conducted from 12/2000 to 12/ 2001 on 1997 medical students at Hå ChÝ Minh City Medico-Pharmaceutical University. 117 students who were negative with HBsAg, anti-HBs and anti-HBc were vaccinated with Merck Sharp & Dohm-produced vaccine. Three consecutive doses of 10mcg vaccine were delivered at 0, 1 and 6 months. Anti-HBs antibody was measured at 7 and 8 months of the study. It was noted that the second antibody titer was the third of first one. In the first assessment all participants had the antibody at protective level (i.e. 10mUI/ml or more), with mean titer was 789±304mUI/ml. 98.1% (105/107) of cases had anti-HBs level of 100mUI/ml or more, and 62.6% (67/107) of cases had reached the level of 1000mUI/ml or more. By 18 months, the mean antibody titer level was 248±209mUI/ml. The frequency distribution of anti-HBs level of 0mUI/ml, £10mUI/ml, 10 to £100mUI/ml, 100 to £1000mUI/ml and ³ 1000mUI/ml was 0 (0%), 1(0.9%), 5(4.7%), 35(32.7%), 59(55.1%) and 7(6.5%), respectively. The difference between two titer measures was statistical significant with p<0.001. However, there was no difference titers of male students (p=0.69) and female students (p=0.24). After 18 months of vaccination, there was only one acquired HBV case with anti-HBc (+) but had no clinical manifestation. No carrier was detected.
Hepatitis B ; Vaccination

From May to December 1999, we performed a study to look for the antibody response after vaccination against hepatitis B in 112-second year medical students (97, Faculty of Medicine, Ho Chi Minh city, VietNam). We used recombinant DNA vaccine (HB VAX- II, MSD), with standard schedule (0,16 months). The healthy students (mean age: 19,7+/- 1,5 mean height 1,6+/- 0,1 m, mean body weight 51,1+/- 6,6 kg) who had neither immunodepression nor previous hepatitis B vaccination were included in this study. The sera from these were negative for HBsAg anti-HBs, anti-HBc. The good immunological response after vaccination was confirmed by the level of anti-HBs >10 m Ul/ml in the sera (blood taken 1 month after the 3rd injection). The results were encouraging: 100% students who received the vaccine got a good response with the height level of anti- HBs in the sera (average: 794+/- 306mU/ml). The level of anti-HBs was below <100mUI/ml in 2 students (1.8%), 100-< 500 in 20(17.8%),500-<1000 in 20 (17.8%) and >= 1000 in 70 (62,5%). These students had no close relationship with the age and the sex.
Hepatitis B ; Vaccination

Recombinant DNA hepatitis B vaccine (RecomBvax)- produced by VABIOTECH -National Institute of Hygiene and Epidemiology was injected into 319 children from 3 to 6 years old living in 3 communes Thieu Long, Thieu Hung and Thieu Hop of Thieu Hoa district, Thanh Hoa province to evaluate quality of the vaccine in clinical. The results showed that RecomBvax vaccine have high safety and have not significant side effect. The incidence of positive immune response of 3 RecomBvax injections is 91,85% with GMT of 350.6mIU/ml while the protective concentration of antibody needed is 10mIU/ml. RecomBvax is highly safe and immunogenic response equivalent with rHbvax in the control group.
Hepatitis B ; DNA, Vaccination

After integrating hepatitis B vaccine produced by National Institute of Hygiene and Epidemiology into the Expanded Program on Immunization (EPI), seropositive rate and geometric mean titre of anti-HBs of 12-24 month old children were 69% and 157 mIU/ml in urban group, respectively. The results were higher than rural group (48.6% and 107.2 mIU/ml, respectively). Seroprotective rate increased from 48.7% to 80.2% after booster dose. This rate was highest (93.3%) in children received the booster dose 8-10 months after primary immunization. In the different time of booster dose, level of anti-HBs of 12-24 month old was higher than before
Hepatitis B ; Vaccination ; child

A horizontal section descriptive study was conducted from September 2001 to May 2002 on the subjects who never been vaccinated previously. The examinations for HBsAg and antiHBs were performed by ELISA technique on ASXYM apparatus before the vaccination. Most of 1841 choosen subjects were of aged 15-19, 20-29 and 30-39 groups. The rate of protected subjects was 35.8%, the least was in the aged group of 10-14. These rates were similar in 2 genders
Hepatitis B ; Hepatitis B virus ; Diseases ; Vaccination

Hepatitis B Vaccines ; Humans ; Vaccination

No abstract available.
Hepatitis B* ; Hepatitis* ; Humans ; Infant, Newborn* ; Vaccination*

Background: Previous studies showed that B hepatitis prevalence in Vietnam was very high and the rate of mother-to-child transmission was range from 44.7% to 45.2%. Objectives: Study on the efficacies of the interventional methods with anti-HBV immunoglobulin and hepatitis B vaccination within 24 hours after birth for neonates in Hanoi. Subjects and method: This interventional study was carried out on 163 neonates of positive-HBsAg mothers who were admitted to Hanoi Obstetrical Hospital from 6/2005 to 3/2007. These neonates received anti-HBV immunoglobulin and hepatitis B vaccination within 24 hours after birth, then were followed up for 11 to 18 months. Results: Among these 163 neonates that received interventions, there were 135 neonates that underwent HBsAg tests after 11 to 18 months. The results showed that only one newborn baby had positive HBsAg (0.74%) and 134 neonates with non-HBV (99.26%). 81.5% of neonates had hepatitis B surface antibody that can protect against HBV. Conclusion: Early interventions with anti-HBV immunoglobulin and HBV vaccination were effective in preventing HBV for neonates of positive-HBsAg mothers.
anti-HBV immunoglobulin ; hepatitis B vaccination ; neonate

Hepatitis B Vaccines ; Humans ; Infant, Newborn ; Vaccination